Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
UPI's Cash to Debt is ranked higher than
91% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. UPI: No Debt )
UPI' s 10-Year Cash to Debt Range
Min: 1.25   Max: No Debt
Current: No Debt

Equity to Asset 0.73
UPI's Equity to Asset is ranked higher than
78% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. UPI: 0.73 )
UPI' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.91
Current: 0.73

0.39
0.91
Interest Coverage No Debt
UPI's Interest Coverage is ranked higher than
93% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 235.10 vs. UPI: No Debt )
UPI' s 10-Year Interest Coverage Range
Min: 3.21   Max: 9999.99
Current: No Debt

3.21
9999.99
F-Score: 4
Z-Score: 4.87
M-Score: -3.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -19.61
UPI's Operating margin (%) is ranked higher than
58% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 5.91 vs. UPI: -19.61 )
UPI' s 10-Year Operating margin (%) Range
Min: -87.55   Max: 15.27
Current: -19.61

-87.55
15.27
Net-margin (%) -19.87
UPI's Net-margin (%) is ranked higher than
58% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.15 vs. UPI: -19.87 )
UPI' s 10-Year Net-margin (%) Range
Min: -73.95   Max: 9.41
Current: -19.87

-73.95
9.41
ROE (%) -40.16
UPI's ROE (%) is ranked higher than
54% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.20 vs. UPI: -40.16 )
UPI' s 10-Year ROE (%) Range
Min: -146.57   Max: 24.87
Current: -40.16

-146.57
24.87
ROA (%) -30.92
UPI's ROA (%) is ranked higher than
56% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.77 vs. UPI: -30.92 )
UPI' s 10-Year ROA (%) Range
Min: -83.79   Max: 15.34
Current: -30.92

-83.79
15.34
ROC (Joel Greenblatt) (%) -321.04
UPI's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 9.15 vs. UPI: -321.04 )
UPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -352.19   Max: 77.16
Current: -321.04

-352.19
77.16
Revenue Growth (3Y)(%) 16.70
UPI's Revenue Growth (3Y)(%) is ranked higher than
91% of the 340 Companies
in the Global Medical Devices industry.

( Industry Median: 5.00 vs. UPI: 16.70 )
UPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.7   Max: 16.7
Current: 16.7

-23.7
16.7
EBITDA Growth (3Y)(%) 6.60
UPI's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 1.60 vs. UPI: 6.60 )
UPI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -38.3   Max: 214.1
Current: 6.6

-38.3
214.1
» UPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

UPI Guru Trades in Q4 2013

Jim Simons 78,100 sh (+6.99%)
» More
Q1 2014

UPI Guru Trades in Q1 2014

Jim Simons 91,300 sh (+16.9%)
» More
Q2 2014

UPI Guru Trades in Q2 2014

Jim Simons 123,178 sh (+34.92%)
» More
Q3 2014

UPI Guru Trades in Q3 2014

Jim Simons 131,033 sh (+6.38%)
» More
» Details

Insider Trades

Latest Guru Trades with UPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.90
UPI's P/B is ranked higher than
66% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. UPI: 4.90 )
UPI' s 10-Year P/B Range
Min: 0.44   Max: 11.07
Current: 4.9

0.44
11.07
P/S 1.97
UPI's P/S is ranked higher than
78% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. UPI: 1.97 )
UPI' s 10-Year P/S Range
Min: 0.38   Max: 11.49
Current: 1.97

0.38
11.49
EV-to-EBIT -8.46
UPI's EV-to-EBIT is ranked lower than
51% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 61.55 vs. UPI: -8.46 )
UPI' s 10-Year EV-to-EBIT Range
Min: -33.4   Max: 0.9
Current: -8.46

-33.4
0.9
Current Ratio 4.04
UPI's Current Ratio is ranked higher than
81% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.79 vs. UPI: 4.04 )
UPI' s 10-Year Current Ratio Range
Min: 1.72   Max: 13.51
Current: 4.04

1.72
13.51
Quick Ratio 3.88
UPI's Quick Ratio is ranked higher than
84% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.01 vs. UPI: 3.88 )
UPI' s 10-Year Quick Ratio Range
Min: 1.34   Max: 13.24
Current: 3.88

1.34
13.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.03
UPI's Price/Net Cash is ranked higher than
93% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 9.03 )
UPI' s 10-Year Price/Net Cash Range
Min: 1.81   Max: 107.2
Current: 9.03

1.81
107.2
Price/Net Current Asset Value 6.53
UPI's Price/Net Current Asset Value is ranked higher than
91% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. UPI: 6.53 )
UPI' s 10-Year Price/Net Current Asset Value Range
Min: 1.32   Max: 26
Current: 6.53

1.32
26
Price/Tangible Book 5.00
UPI's Price/Tangible Book is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 6.92 vs. UPI: 5.00 )
UPI' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 12.77
Current: 5

0.76
12.77
Price/Median PS Value 0.66
UPI's Price/Median PS Value is ranked higher than
93% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. UPI: 0.66 )
UPI' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.81
Current: 0.66

0.14
4.81
Earnings Yield (Greenblatt) -11.80
UPI's Earnings Yield (Greenblatt) is ranked higher than
53% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. UPI: -11.80 )
UPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 113.7   Max: 786.1
Current: -11.8

113.7
786.1

Analyst Estimate

Mar15 Mar16
Revenue(Mil) 27 30
EPS($) -0.22 -0.16
EPS without NRI($) -0.22 -0.16

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Uroplasty Inc was incorporated on January 21, 1992 as a Minnesota corporation. It is a medical device company. It develops, manufactures and markets innovative, proprietary products for the treatment of voiding dysfunctions. Its primary focus is on two products: the Urgent PC Neuromodulation System, and Macroplastique Implants. The Urgent PC Neuromodulation System delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The Macroplastique Implants is an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. The Company is focusing its sales and marketing efforts primarily on urologists, urogynecologists and gynecologists with significant office-based and outpatient surgery-based patient volume. The testing, manufacturing, promotion, marketing and distribution of the Company's products in the United States, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies.
» More Articles for UPI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Sep 02 2013 
Uroplasty Inc Reports Operating Results (10-K/A) Feb 22 2011 
Uroplasty Inc (UPI) COO Susan Hartjes Holman sells 12,000 Shares Feb 04 2011 
Uroplasty Inc Reports Operating Results (10-Q) Jan 27 2011 
Uroplasty Inc Reports Operating Results (10-Q) Oct 27 2010 
Uroplasty Inc Reports Operating Results (10-K/A) Jun 18 2010 
Uroplasty Inc Reports Operating Results (10-Q) Feb 01 2010 
Uroplasty Inc Reports Operating Results (10-Q) Nov 02 2009 
Uroplasty Inc Reports Operating Results (10-Q) Aug 04 2009 
Uroplasty Reports First Fiscal Quarter Results Aug 03 2009 

More From Other Websites
UROPLASTY INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Medical Device Company Positioned for Growth Dec 22 2014
Uroplasty and Vision-Sciences to Merge, Creating Innovative Medical Device Company Positioned for... Dec 22 2014
Uroplasty To Participate In The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum Nov 13 2014
Uroplasty To Participate In The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum Nov 13 2014
10-Q for Uroplasty, Inc. Nov 03 2014
UROPLASTY INC Files SEC form 10-Q, Quarterly Report Oct 31 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Oct 24 2014
Uroplasty Inc Earnings Call scheduled for 4:30 pm ET today Oct 23 2014
UROPLASTY INC Files SEC form 8-K, Results of Operations and Financial Condition Oct 23 2014
Uroplasty Reports Record Fiscal Second Quarter Revenue Oct 23 2014
Q2 2015 Uroplasty Inc Earnings Release - After Market Close Oct 23 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 15 2014
Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board of Directors Oct 15 2014
Healthcare Industry Leader Kenneth H. Paulus Joins Uroplasty's Board of Directors Oct 15 2014
Uroplasty to Announce Second Quarter Fiscal Year 2015 Financial Results on October 23, 2014 Oct 09 2014
UROPLASTY INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Oct 03 2014
Uroplasty To Participate In The 5th Annual Craig-Hallum Alpha Select Conference Sep 10 2014
UROPLASTY INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK